Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Current positioning and future development of belantamab mafodotin and other antibody-drug conjugates to treat multiple myeloma.

Frontiers in oncology·2026
Same author

MDM2 Drives Proteasome Inhibitor Resistance and Represents a TP53-Independent Therapeutic Vulnerability in Multiple Myeloma.

Cells·2026
Same author

Bedaquiline amplifies proteasome inhibitor efficacy and overcomes resistance in multiple myeloma.

Haematologica·2026
Same author

Alnuctamab, a bivalent B-cell maturation antigen-targeting T cell engager for patients with relapsed or refractory multiple myeloma: results from a phase 1, first-in-human study.

Leukemia·2026
Same author

Efficacy and safety of teclistamab in triple-class exposed relapsed/refractory multiple myeloma: Pooled findings from three clinical cohorts and a retrospective cohort.

Cancer·2026
Same author

Extramedullary Disease-Achilles Heel in Myeloma?

American journal of hematology·2025

Related Experiment Video

Updated: Aug 31, 2025

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

12.0K

Melphalan flufenamide for relapsed/refractory multiple myeloma.

Omar Nadeem1, Maria-Victoria Mateos2, Yvonne A Efebera3

  • 1Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.

Drugs of Today (Barcelona, Spain : 1998)
|August 19, 2022
PubMed
Summary
This summary is machine-generated.

Melphalan flufenamide, a novel peptide-drug conjugate, shows promise for relapsed/refractory multiple myeloma (RRMM). Despite market withdrawal and ongoing reviews, its unique mechanism offers potential new therapeutic options for RRMM patients.

Keywords:
DNA alkylating drugsHematologic malignanciesMelflufenMelphalan flufenamideMultiple myeloma

More Related Videos

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
07:53

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

4.3K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.5K

Related Experiment Videos

Last Updated: Aug 31, 2025

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

12.0K
Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
07:53

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

4.3K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.5K

Area of Science:

  • Hematologic Oncology
  • Drug Development
  • Pharmacology

Background:

  • Multiple myeloma (MM) is a largely incurable blood cancer with significant unmet needs in relapsed/refractory cases (RRMM).
  • Existing therapies for RRMM, particularly triple-class-refractory disease, require novel mechanisms of action.
  • Melphalan flufenamide (melflufen) represents a new class of alkylating peptide-drug conjugates.

Purpose of the Study:

  • To review the novel mechanism of action and pharmacokinetics of melflufen.
  • To summarize key efficacy and safety data from clinical studies supporting melflufen's initial approval.
  • To discuss the complexities and nuances of the Phase III OCEAN study data.

Main Methods:

  • Review of preclinical and clinical data for melflufen.
  • Analysis of pharmacokinetic and pharmacodynamic properties.
  • Evaluation of efficacy and safety outcomes in RRMM patients.

Main Results:

  • Melflufen demonstrated efficacy and manageable safety in combination with dexamethasone for heavily pretreated RRMM patients.
  • Initial analyses of the OCEAN study led to a voluntary market withdrawal, but subsequent data prompted a rescission.
  • Regulatory reviews by the U.S. FDA and European Medicines Agency (EMA) are ongoing.

Conclusions:

  • Melflufen's novel mechanism targeting aminopeptidases shows potential in treating RRMM.
  • Peptide-drug conjugates represent a promising therapeutic strategy for overcoming resistance in multiple myeloma.
  • Further evaluation and regulatory discussions are crucial for melflufen's future in RRMM treatment.